



NDA 202971/S-020

**SUPPLEMENT APPROVAL**

Otsuka Pharmaceutical Company, Ltd.  
c/o OPDC  
Attention: Hoa Van  
Senior Manager, Global Regulatory Affairs  
508 Carnegie Center Drive  
Princeton, NJ 08540

Dear Ms. Van:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 31, 2025, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension.

This Prior Approval supplemental new drug application provides for updated text placement and prominence in order to accommodate the placement of a new security seal and addition of country of origin.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the patient package insert) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission **“Product Correspondence – Final Printed Carton and Container Labels for approved NDA 202971/S-020.”** Approval of this submission by FDA is not required before the labeling is used.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Mikee Aguirre, Regulatory Business Process Manager, at [mikee.aguirre@fda.hhs.gov](mailto:mikee.aguirre@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Vilayat Sayeed, Ph.D.  
Director, Division of Product Quality Assessment II  
Office of Product Quality Assessment I  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosures:

Carton and Container Labeling



Vilayat  
Sayeed

Digitally signed by Vilayat Sayeed  
Date: 1/28/2026 07:00:29AM  
GUID: 508da70600028a7aad41a1cc455d8261